La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

ANGLE Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Andrew David Newland

Amministratore delegato

UK£281.0k

Compenso totale

Percentuale dello stipendio del CEO	95.7%
Mandato del CEO	20.4yrs
Proprietà del CEO	2.3%
Durata media del management	1.6yrs
Durata media del Consiglio di amministrazione	9.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Andrew David Newland rispetto agli utili di ANGLE?
Data	Compenso totale	Stipendio	Guadagni aziendali
Dec 31 2023	UK£281k	UK£269k	-UK£20m
Sep 30 2023	n/a	n/a	-UK£21m
Jun 30 2023	n/a	n/a	-UK£22m
Mar 31 2023	n/a	n/a	-UK£22m
Dec 31 2022	UK£264k	UK£253k	-UK£22m
Sep 30 2022	n/a	n/a	-UK£19m
Jun 30 2022	n/a	n/a	-UK£17m
Mar 31 2022	n/a	n/a	-UK£16m
Dec 31 2021	UK£446k	UK£242k	-UK£15m
Sep 30 2021	n/a	n/a	-UK£15m
Jun 30 2021	n/a	n/a	-UK£16m
Mar 31 2021	n/a	n/a	-UK£14m
Dec 31 2020	UK£392k	UK£240k	-UK£12m
Jun 30 2020	n/a	n/a	-UK£10m
Mar 31 2020	n/a	n/a	-UK£11m
Dec 31 2019	UK£244k	UK£160k	-UK£11m
Oct 31 2019	n/a	n/a	-UK£10m
Jul 31 2019	n/a	n/a	-UK£9m
Apr 30 2019	n/a	n/a	-UK£9m
Jan 31 2019	n/a	n/a	-UK£9m
Oct 31 2018	n/a	n/a	-UK£8m
Jul 31 2018	n/a	n/a	-UK£8m
Apr 30 2018	UK£336k	UK£229k	-UK£8m

Compensazione vs Mercato: La retribuzione totale di Andrew David ($USD 365.03K ) è circa la media per le aziende di dimensioni simili nel mercato UK ($USD 369.30K ).

Compensazione vs guadagni: La retribuzione di Andrew David è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Andrew David Newland (63 yo)

20.4yrs

Mandato

UK£281,000

Compensazione

Mr. Andrew David William Newland, Meng, ACA founded ANGLE Plc in 1994 and serves as its Group Chief Executive. Mr. Newland founded Provexis, the first ever spin-out of Rowett Institute, Europe’s leading nu...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Andrew David Newland	Founder	no data	UK£281.00k	2.26% £ 949.6k
Ian Griffiths	CFO, Finance Director	7.2yrs	UK£180.00k	0.39% £ 165.3k
Martin Cooke	Director of Operations & Regulatory Affairs	6.6yrs	Nessun dato	Nessun dato
Karen Miller	Chief Scientific Officer	1.6yrs	Nessun dato	Nessun dato
Andrew Holder	Head of Investor Relations	no data	Nessun dato	Nessun dato
Anne-Sophie Pailhes-Jimenez	Head of R&D and Senior Director	less than a year	Nessun dato	Nessun dato
Brett Swansiger	Chief Commercial Officer	1.6yrs	Nessun dato	Nessun dato
Nick Claxton	Senior Vice President of Commercial Operations	1.6yrs	Nessun dato	Nessun dato

1.6yrs

Durata media

58yo

Età media

Gestione esperta: Il team dirigenziale di AGL non è considerato esperto (durata media 1.6 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Andrew David Newland	Founder	20.4yrs	UK£281.00k	2.26% £ 949.6k
Ian Griffiths	CFO, Finance Director	20.4yrs	UK£180.00k	0.39% £ 165.3k
Harold Swerdlow	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Juliet Thompson	Non-Executive Director	1.6yrs	UK£48.00k	Nessun dato
Ashok Venkitaraman	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Brian Howlett	Non-Executive & Senior Independent Director	11.6yrs	UK£27.00k	0.0031% £ 1.3k
Jan Groen	Independent Non-Executive Chairman	5.8yrs	UK£50.00k	Nessun dato
Clive Stanway	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Adrian Newland	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
James Reuben	Member of Scientific Advisory Board	9.2yrs	Nessun dato	Nessun dato
Daniel Danila	Member of Scientific Advisory Board	9.1yrs	Nessun dato	Nessun dato
Greg Shaw	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato

9.2yrs

Durata media

63yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di AGL sono considerati esperti (durata media dell'incarico 9.2 anni).

ANGLE Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

ANGLE plc, Annual General Meeting, Jun 26, 2024

ANGLE plc Announces Senior Management Appointments

ANGLE plc Announces Board Changes

ANGLE plc Announces Appointment of Joseph (Joe) Eid as Non-Executive Director

Insufficient new directors

ANGLE plc Announces Appointment of Juliet Thompson as Non-Executive Director

Recent updates

Angle plc Announces the Publication of One of the Company's Clinical Studies That Was Submitted to the FDA for De Novo Regulatory Clearance of the Parsortix PC1 System

New minor risk - Shareholder dilution

Full year 2023 earnings released: UK£0.077 loss per share (vs UK£0.088 loss in FY 2022)

ANGLE plc Provides Revenue Guidance for the First Half of 2024

ANGLE plc to Report Q4, 2023 Results on Jun 07, 2024

ANGLE plc Announces Publication of Study Using the Parsortix System

ANGLE plc, Annual General Meeting, Jun 26, 2024

We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate

Consensus revenue estimates decrease by 17%

Consensus revenue estimates decrease by 17%

Price target increased by 15% to UK£1.09

Angle plc Announces Use of Parsortix System in Pre-Clinical Model Unlocks Opportunities for Drug Discovery

ANGLE plc Launches Portrait+ CTC Kit At SABCS

Will ANGLE (LON:AGL) Spend Its Cash Wisely?

ANGLE plc Provides Earnings Guidance for the Year 2023

ANGLE plc Announces the Launch of Its Portrait® PD-L1 Test for the Evaluation of PD-L1 Protein Expression on CTCs Following Extensive Development and Optimisation

First half 2023 earnings released: UK£0.038 loss per share (vs UK£0.039 loss in 1H 2022)

Angle plc Announces the Launch of Its Portrait™ Flex Ctc Assay

We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ANGLE plc Announces Senior Management Appointments

ANGLE plc Announces Board Changes

Price target decreased by 35% to UK£0.94

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

ANGLE plc Announces Appointment of Joseph (Joe) Eid as Non-Executive Director

Insufficient new directors

ANGLE plc to Report Fiscal Year 2022 Results on Jun 02, 2023

ANGLE plc Announces Appointment of Juliet Thompson as Non-Executive Director

ANGLE plc Announces the Publication of Results from A Multi-Centre Clinical Study

Angle plc Announces It Presented Results from A Proof of Concept Study At the International Society of Liquid Biopsy Meeting in Miami, Florida

ANGLE plc Announces Streamlining of Operations to Increase Cash Runway

First half 2022 earnings: EPS and revenues miss analyst expectations

ANGLE plc Announces Positive Headline Results from Ovarian Study

ANGLE plc Announces Study Using Parsortix in Head and Neck Cancer

ANGLE plc Announces the Publication of Results from A Clinical Study Undertaken in Partnership with the Wilmot Cancer Institute, University of Rochester, NY, US

Price target increased to UK£2.16

Angle plc Announces New Study Highlights Use of Parsortix System to Enable Cancer Cell Dna Analysis in Non-Small Cell Lung Cancer

ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

ANGLE plc Announces Ground-Breaking Research by the World-Class Team at the Molecular Oncology Laboratory at the Swiss Federal Institute of Technology Zurich, Switzerland

Angle plc Announces Results of Work Undertaken in Advanced Non-Small Cell Lung Cancer (NSCLC) and Sarcoma Patients

Angle plc Receives FDA Clearance for Parsortix

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Price target increased to UK£1.85

Insufficient new directors

ANGLE plc, Annual General Meeting, Jun 29, 2022

ANGLE plc to Report Fiscal Year 2021 Results on Apr 28, 2022

Angle Announces Parsortix System Shows Potential for Providing Rapid Information on Patient Response to Therapies Targeting Metastasis

ANGLE plc Announces the Edith Cowan University, Perth, Australia, Has Published Results from A Study in Ovarian Cancer Patients Using the Parsortix® System

Price target increased to UK£1.80

ANGLE plc Announces the Publication of Research Undertaken by the World-Class Team At the University of Southern California Norris Cancer Center

ANGLE plc Provides Update on Lab Accreditation and Ovarian Study

Insufficient new directors

First half 2021 earnings released: UK£0.036 loss per share (vs UK£0.02 loss in 1H 2020)

ANGLE plc Announces Parsortix System Demonstrates Ability to Isolate CTCS for Downstream Gene Analysis Revealing Multiple Prognostic Biomarkers

Angle plc Announces That the Health Research Institute of Santiago

CFO, Finance Director exercised options to buy UK£524k worth of stock.

ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

Founder exercised options and sold UK£1.0m worth of stock

Forecast to breakeven in 2025

ANGLE plc Announces Published Results of A New Study Undertaken in Non-Small Cell Lung Cancer

Angle plc Announces Breakthrough Research Supports Potential Use of Parsortix in Prevention of Relapse of Breast Cancer Patients in Remission

Angle's Parsortix System Harvests Intact CTCs for Whole Genomic Sequencing Identifying Multiple Druggable Targets

We're Not Very Worried About ANGLE's (LON:AGL) Cash Burn Rate

Full year 2020 earnings released: UK£0.065 loss per share (vs UK£0.057 loss in FY 2019)

ANGLE plc Announces Patient Enrolment Completed in Ovarian Cancer Clinical Verification Study

Angle plc Provides Update on Submission for FDA Clearance of the Parsortix System

What Type Of Shareholders Make Up ANGLE plc's (LON:AGL) Share Registry?